“Mind the Gap” Revisited

We note with interest the article by Evans et al recently published in Seminars in Oncology [1]. The authors compared access to cancer medicines in New Zealand and Australia and examined the potential foregone population health gains due to differences in the ready availability of anti-cancer pharmaceuticals in each country. However, we are concerned that the authors have used a flawed methodological approach in making such comparisons and failed to address the potential role of access to pharmaceuticals available in many other developed countries, to the fundamental differences in cancer survival between the two countries.

Source: Seminars in Oncology - August 2, 2017 Category: Cancer & Oncology Authors: John R. Zalcberg, Michael Wonder Source Type: research